Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Abstract: The present invention relates to transdermal therapeutic systems that include an occlusive back layer impervious to an active substance, a single or multilayer matrix, and a peelable protective film. The matrix or at least one of the matrix layers includes a pharmaceutical active substance or a plurality of pharmaceutical active substances in the form of at least one pharmaceutically consumable salt thereof and a pharmaceutically consumable, alkaline reacting oxide.

Abstract: A device and a method for determining a suitability of an active ingredient to be applied transdermally or transmucosally. In particular, a system that includes: at least one input device for inputting at least one designation of an active ingredient; a database for storing a plurality of data at least relating to the active ingredient; a computing unit for assessing a suitability of the active ingredient to be applied transdermally and/or transmucosally while taking into consideration data entered via the input device and/or data stored in the database; and an output device for displaying the assessed suitability.

Abstract: The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy.

Abstract: The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy.

Abstract: The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy.

Abstract: The present invention relates to transdermal therapeutic systems that include an occlusive back layer impervious to an active substance, a single or multilayer matrix, and a peelable protective film. The matrix or at least one of the matrix layers includes a pharmaceutical active substance or a plurality of pharmaceutical active substances in the form of at least one pharmaceutically consumable salt thereof and a pharmaceutically consumable, alkaline reacting oxide.

Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.

Abstract: The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy.

Abstract: A hydrophile gel system for cosmetic and/or skin care applications. The gel system comprises a detachable carrier film and a hydrogel which contains at least 15 percent by weight of karaya gum and whose water content is less than 5 percent by weight.

Abstract: Medical skin patches for treating colds by releasing essential oils through evaporation comprising a backing layer permeable to gas and water vapour and a hydrophile and pressure-sensitive adhesive polymer matrix connected to the backing layer. The matrix contains at least one essential oil, at least one hydrophile polymer, at least one substance having an adsorbent effect or/and at least one substance having an emulsifying effect, and at least one pressure-sensitive adhesive polymer. The water content of the matrix is less than 5% by weight, or even less than 1% by weight.